Pacific Biosciences Of California Stock News

Wells Fargo & Company MN boosted its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 25.2% during the second quarter, Holdings Channel reports. The firm owned 237,563 shares of the biotechnology companys stock after acquiring an additional 47,789 shares during the quarter. Wells Fargo & Company MNs holdings in Pacific Biosciences of []

AdvisorNet Financial Inc lowered its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 2.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 27,852 shares of the biotechnology companys stock after selling 700 shares during the quarter. AdvisorNet Financial Incs holdings in Pacific Biosciences of California were worth $712,000 at the []

Pacific Biosciences of California Inc. (NASDAQ:PACB) traded at $23.06 at close of the session on Monday, 11/29/21, made a downward move of -1.11% on its previous days price. Looking at the stock we see that its previous close was $23.32 and the beta (5Y monthly) reads 1.06 with the days price range being $22.305 What You Didnt Know About Pacific Biosciences of California Inc. (NASDAQ: PACB) This Week Read More »

Analysts expect that Pacific Biosciences of California, Inc. (NASDAQ:PACB) will post ($0.29) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Pacific Biosciences of Californias earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.29). Pacific Biosciences of California []

Equities analysts expect that Pacific Biosciences of California, Inc. (NASDAQ:PACB) will report ($0.29) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Pacific Biosciences of Californias earnings, with estimates ranging from ($0.29) to ($0.28). Pacific Biosciences of California reported earnings of ($0.01) per share during the same []

Analysts expect Pacific Biosciences of California, Inc. (NASDAQ:PACB) to report sales of $35.38 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Pacific Biosciences of Californias earnings, with the highest sales estimate coming in at $35.85 million and the lowest estimate coming in at $34.90 million. Pacific Biosciences of []

Pacific Biosciences of California Inc. (NASDAQ:PACB) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 2.27% to the previous days close as strong demand from buyers drove the stock to $23.39. Actively observing the price movement in the last trading, the stock closed the session at $22.87, falling within a range Pacific Biosciences of California Inc. (NASDAQ: PACB) Is A Blank Check For Growth Read More »

Pacific Biosciences of California, Inc. (NASDAQ:PACB)s stock price was down 5.7% during mid-day trading on Monday . The company traded as low as $24.95 and last traded at $24.95. Approximately 6,503 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 2,959,705 shares. The stock had previously closed at []

Equities analysts forecast that Pacific Biosciences of California, Inc. (NASDAQ:PACB) will report sales of $35.38 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Pacific Biosciences of Californias earnings, with the lowest sales estimate coming in at $34.90 million and the highest estimate coming in at $35.85 million. []

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

Wall Street analysts forecast that Pacific Biosciences of California, Inc. (NASDAQ:PACB) will report ($0.29) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Pacific Biosciences of Californias earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.28). []

MENLO PARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (RSUs) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on November 15, 2021.

Pacific Biosciences of California Inc. (NASDAQ:PACB) price on Wednesday, November 17, fall -3.60% below its previous days close as a downside momentum from buyers pushed the stocks value to $27.05. A look at the stocks price movement, the close in the last trading session was $28.06, moving within a range at $26.70 and $28.00. The Pacific Biosciences of California Inc.s (NASDAQ:PACB) Stock Price Rises 4.28% This Year: A Look At Likely Future Paths Read More »

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

Related Stocks: ASND , PACB , TVTX , LEGN , KYMR , BLUE , DICE , SRZN , TCRX , TNGX , AMYT , LIFE , APLS , ADCT , PTGX , ASMB , ISEE , SBTX ,